ROS Signaling in Endothelial Function

Not Applicable

Completed

• Conditions: Cardiovascular Disease
• Interventions: Drug: Placebo; Drug: N-acetylcysteine

• Registration Number: NCT01037465
• Lead Sponsor: Boston University

Brief Summary

The vascular endothelium (inner lining of cells in blood vessels) normally prevents vasospasm and thrombosis by producing nitric oxide and other regulatory substances. In patients with atherosclerosis, endothelial function is impaired. Excess production of reactive oxygen species (free radicals) contribute to endothelial dysfunction in atherosclerosis, and some prior studies have shown a beneficial effect of antioxidant treatment on endothelial function in patients with coronary artery disease. On the other hand, reactive oxygen species may be required for normal endothelial function and antioxidant supplements failed to show a benefit in large clinical trials. The effect of antioxidant treatment on endothelial function in healthy subjects is unknown. The present study will test the hypothesis that scavenging reactive species might reduce endothelium-dependent vasodilation in healthy subjects.

The study is a randomized, double-blind, placebo-controlled crossover study. Participants will receive 2.4 grams of oral NAC or similar-appearing placebo during the first visit, and then will cross over to the alternative treatment (NAC or placebo) for the second and final visit. We will examine endothelial function before and after treatment on each visit.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-09
• Study First Submitted: 2009-12-19
• Study First Submitted QC: 2009-12-21
• Study First Posted: 2009-12-23
• Primary Completion: 2015-12
• Study Completion: 2016-03-26
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-08
• Last Update Posted: 2017-03-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

1. Sex: Male and Female subjects.
2. Age range: 21-65 years old.
3. Disease status: No acute, chronic, or debilitating medical condition or use of prescribed medications.
4. Willingness and ability to provide written informed consent and the ability to understand, to participate and to comply with the study requirements.

Exclusion Criteria

1. Women with a positive urine beta HCG pregnancy test and lactating women.
2. Blood pressure greater than 140/90 mmHg; serum LDL cholesterol greater than 160 mg/dl; fasting blood sugar greater than 110 mg/dl.
3. History of any cigarette smoking within one year of the study.
4. Clinical history of any acute, chronic, or debilitating medical condition, including liver disease and peptic ulcer disease.
5. Treatment with an investigational new drug within the last 30 days.
6. History of a psychological illness or condition such as to interfere with the subject's ability to understand the requirements of the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Placebo
N-acetylcysteine	N-acetylcysteine	N-acetylcysteine

Primary Outcome Measures

Name	Time	Method
Brachial artery flow-mediated dilation	4 hours

Secondary Outcome Measures

Name	Time	Method
Blood markers of antioxidant capacity	4 hours

Trial Locations

Locations (1)

Boston Medical Center; 🇺🇸 Boston, Massachusetts, United States